Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine
- PMID: 24523483
- DOI: 10.1212/WNL.0000000000000223
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine
Abstract
Objective: We compared the efficacy of IV valproate with metoclopramide and with ketorolac in patients presenting to an emergency department (ED) with acute migraine.
Methods: This was a double-blind comparative efficacy trial. Patients were randomized to 1,000 mg sodium valproate, 10 mg metoclopramide, or 30 mg ketorolac, each administered as an IV drip over 15 minutes. The primary outcome was improvement in headache by 1 hour, measured on a verbal 0 to 10 scale, at baseline and 60 minutes later. Important secondary outcomes included (1) need for rescue medication in the ED, and (2) sustained headache freedom.
Results: Three hundred thirty patients were enrolled over 30 months beginning in October 2010. Baseline characteristics were comparable among the 3 arms. On the primary outcome, patients receiving IV valproate improved by a mean of 2.8 (95% confidence interval [CI]: 2.3, 3.3) on the 0 to 10 scale; those receiving IV metoclopramide improved by 4.7 (95% CI: 4.2, 5.2); and those receiving IV ketorolac improved by 3.9 (95% CI: 3.3, 4.5). On the secondary endpoints, 69% (95% CI: 60%, 78%) of patients receiving valproate required rescue medication, compared with 33% (95% CI: 24%, 42%) of metoclopramide patients and 52% (95% CI: 42%, 63%) of those assigned to ketorolac. Sustained headache freedom was achieved in 4% (95% CI: 0%, 7%) of those randomized to valproate, 11% (95% CI: 5%, 17%) of metoclopramide patients, and 16% (95% CI: 9%, 23%) receiving ketorolac. In the metoclopramide arm, 6% (95% CI: 3%, 12%) of patients reported feeling "very restless" after investigational medication administration.
Conclusions: Valproate was less efficacious than either metoclopramide or ketorolac. Metoclopramide demonstrated superiority to ketorolac on several endpoints.
Classification of evidence: This study provides Class I evidence that in ED patients with acute migraine, IV valproate is inferior to metoclopramide or ketorolac in improving headache outcomes.
Comment in
-
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine.Neurology. 2014 Oct 7;83(15):1388-9. doi: 10.1212/01.wnl.0000455698.16732.0a. Neurology. 2014. PMID: 25288700 No abstract available.
-
Author response.Neurology. 2014 Oct 7;83(15):1389. Neurology. 2014. PMID: 25419557 No abstract available.
-
Author response.Neurology. 2014 Oct 7;83(15):1389. Neurology. 2014. PMID: 25512978 No abstract available.
Similar articles
-
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine.Neurology. 2014 Oct 7;83(15):1388-9. doi: 10.1212/01.wnl.0000455698.16732.0a. Neurology. 2014. PMID: 25288700 No abstract available.
-
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.Ann Emerg Med. 2003 Jun;41(6):847-53. doi: 10.1067/mem.2003.195. Ann Emerg Med. 2003. PMID: 12764341 Clinical Trial.
-
Author response.Neurology. 2014 Oct 7;83(15):1389. Neurology. 2014. PMID: 25419557 No abstract available.
-
Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications.Headache. 2012 Mar;52(3):467-82. doi: 10.1111/j.1526-4610.2012.02097.x. Headache. 2012. PMID: 22404708 Review.
-
Intravenous ketorolac versus metoclopramide in adult patients with migraine headaches: An updated systematic review and meta-analysis.Adv Clin Exp Med. 2024 Jul;33(7):661-667. doi: 10.17219/acem/171697. Adv Clin Exp Med. 2024. PMID: 37849443 Review.
Cited by
-
Dopaminergic Projections from the Hypothalamic A11 Nucleus to the Spinal Trigeminal Nucleus Are Involved in Bidirectional Migraine Modulation.Int J Mol Sci. 2023 Nov 28;24(23):16876. doi: 10.3390/ijms242316876. Int J Mol Sci. 2023. PMID: 38069205 Free PMC article.
-
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.BMC Neurol. 2023 Jun 8;23(1):221. doi: 10.1186/s12883-023-03259-7. BMC Neurol. 2023. PMID: 37291500 Free PMC article.
-
Non-opioid Intravenous Drugs for Pain Management in Patients Presenting with Acute Migraine Pain in the Emergency Department: A Comprehensive Literature Review.Anesth Pain Med. 2022 Nov 22;12(5):e132904. doi: 10.5812/aapm-132904. eCollection 2022 Oct. Anesth Pain Med. 2022. PMID: 36937180 Free PMC article. Review.
-
Pain reduction and adverse effects of intravenous metoclopramide for acute migraine attack: A systematic review and meta-analysis of randomized-controlled trials.World J Methodol. 2022 Jul 20;12(4):319-330. doi: 10.5662/wjm.v12.i4.319. eCollection 2022 Jul 20. World J Methodol. 2022. PMID: 36159095 Free PMC article.
-
Trends in the Management of Headache Disorders in US Emergency Departments: Analysis of 2007-2018 National Hospital Ambulatory Medical Care Survey Data.J Clin Med. 2022 Mar 3;11(5):1401. doi: 10.3390/jcm11051401. J Clin Med. 2022. PMID: 35268492 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials